Abstract: Provided herein are compounds, compositions, and methods useful for inhibiting protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and for treating related diseases, disorders, and conditions favorably responsive to PTPN1 or PTPN2 inhibitor treatment, e.g., a cancer or a metabolic disease.

Abstract: Provided herein are compounds, compositions, and methods useful for inhibiting protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and for treating related diseases, disorders, and conditions favorably responsive to PTPN1 or PTPN2 inhibitor treatment, e.g., a cancer or a metabolic disease.

Abstract: Provided herein are compounds, compositions, and methods useful for inhibiting protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and for treating related diseases, disorders, and conditions favorably responsive to PTPN1 or PTPN2 inhibitor treatment, e.g., a cancer or a metabolic disease.

Abstract: A hybrid cable including: a jacket portion; a duct portion configured to be located inside the jacket portion; and an electrical conductor configured to be located inside the jacket portion. The electrical conductor is configured to be located outside of the duct portion; the electrical conductor and the duct portion extend substantially parallel to each other in the jacket portion; the duct portion is configured to be installed in the jacket portion in an empty state of the duct portion in which no wire or cable is in the duct portion; and the duct portion is configured to be loaded with fiber optic cable before, during, and after the hybrid cable is installed at an installation site so as to allow an installer to install an installation required number of fiber optic cables in the duct portion, thereby avoiding installation of unneeded fiber optic cable.

Abstract: The present invention relates to compounds of Formula I, a stereoisomer, enantiomer, a pharmaceutically acceptable salt or an amino acid conjugate thereof; wherein variables are as defined herein; and their pharmaceutical compositions, which are useful as modulators of the activity of Farnesoid X receptors (FXR).

Abstract: The present invention relates to compounds of Formula I, a stereoisomer, enantiomer, a pharmaceutically acceptable salt or an amino acid conjugate thereof; wherein variables are as defined herein; and their pharmaceutical compositions, which are useful as modulators of the activity of Farnesoid X receptors (FXR).

Abstract: A vegetation treatment system includes at least one distribution apparatus, a transport such as a vehicle, having a receptacle for housing a vegetation treatment, and a funnel that facilitates passage of the vegetation treatment from the receptacle to each distribution apparatus. When in use, the vegetation treatment system may be used by an operator to target specific areas for vegetation treatment, particularly where treatments are applied to bedded crops. Each distribution apparatus is mounted onto the transport for application of the treatment. The system also includes one or more mechanisms that articulate each distribution apparatus such that they can be stowed.

Abstract: A vegetation treatment system includes at least one distribution apparatus, a transport such as a vehicle, having a receptacle for housing a vegetation treatment, and a funnel that facilitates passage of the vegetation treatment from the receptacle to each distribution apparatus. When in use, the vegetation treatment system may be used by an operator to target specific areas for vegetation treatment, particularly where treatments are applied to bedded crops. Each distribution apparatus is mounted onto the transport for application of the treatment. The system also includes one or more mechanisms that articulate each distribution apparatus such that they can be stowed.

Abstract: The invention provides novel compounds of the Formula (I) that stimulate rates of glucose oxidation in myocardial cells: wherein W, Cyc, p, Y, X, Z, R, R1, R2, R3, R4, i and n are as defined for Formula (I) herein. The invention also relates to pharmaceutical compositions comprising compounds capable of stimulation of glucose oxidation, methods for increasing glucose oxidation rates in myocardial cells, and methods of treatment of myocardial ischemia.

Abstract: The invention provides novel compounds of the Formula (I) that stimulate rates of glucose oxidation in myocardial cells: 1